Table 1.
Age (Years)/Sex | Presentation | Tumor Primary Site | IHC | Gene Mutation | Recurrence | Tumor Metastasis Site | Treatment | Follow-up and Prognosis | Reference |
---|---|---|---|---|---|---|---|---|---|
55/F | A sudden slurred speech | Nasopharynx | Highly expressed PD-L1 | Tertiary mutations in NSD1 and SOX9 genes | 1 month | Skull base, slope and pterygoid sinus | Surgery, radiotherapy and immunotherapy (PD-L1 inhibitor Sintilimab) | Better than before to date | This case |
19/M | Macroscopic hematuria and progressive anemia | Bladder | ALK pos | NA | 7 months | Lung and left iliac bone and | Surgery and targeted therapy | Complete remission | Bonvini et al, 20218 |
16/M | NR | Right chest wall with pleural involvement | ALK neg, highly expressed PD-L1 | TFG-ROS1 fusion, an acquired G2032R mutation in the TKD of ROS1 and MAPK1 amplification | Continuing progression | Brain, right triceps | Antiinflammatory therapy, chemotherapy, targeted therapy and immunotherapy (PD-L1 inhibitor Nivolumab) | Died of respiratory complications | Carcamo et al, 20219 |
40/M | Dyspnoea and productive cough | Upper lobe of right lung | ALK pos | TPM4-ALK fusion | Transient improvement and continuing progression | Hilar lymph nodes, right trapezius muscle, left frontal lobe, left adrenal, left gluteal | Chemotherapy, radiotherapy and targeted therapy | Dead | Wong et al, 202010 |
57/F | Tightening sensation around the retrosternal region | Anterior mediastinum with left pleural invasion | ALK neg | 6 germline mutations (PARP1 p.V69I, ATR p.S1007N, GRM8 p.T97A, MLLT10 p.G409R, TCF7L2 p.N185S, SMARCA4 p.A321T) and 1 somatic mutation (TSHR p.Q720H) | Recurring at the left anterior mediastinum after nine months post first surgery, and at the left anterior mediastinum and right anterior pleural space at the age of 65 | Left anterior mediastinum and right anterior pleural space | Surgery and radiotherapy | NR | Hou et al, 202011 |
59/M | Consistent fatigue | Medium lobe of right lung | ALK neg | NA | Continuing progression | Bone and abdominal cavity | Targeted therapy | Stable condition on follow-up 9 months | Liu et al, 201912 |
81/M | Anal pain | The posterior rectal wall | ALK neg | NA | 2 months after surgery | Liver | Surgery | Dead | Shimodaira et al, 202013 |
76/M | Upper back pain and motor weakness | Upper lobe of right lung | ALK neg | NA | NA | Right renal hilum | Hormonotherapy and radiotherapy | Improvement in symptoms on follow-up 1 month | Na et al, 201814 |
55/M | Left pneumonia | Lower lobe of left lung | NA | NA | 3 months after first surgery | Lingula, lung and liver | Surgery and radiotherapy | The patient was referred to another oncological center. | Rodrigues et al, 201715 |
37/F | Cough and stridor | Upper lobe of left lung | ALK pos | NA | 1 year after first surgery | Uterine | Surgery | Dead 1 year after second surgery | Zhang et al, 201816 |
18/F | Headaches | Lung | ALK pos | ALK-1 gene rearranged | Continuing progression | Brain | Targeted therapy | Alive and well on follow-up 2.5 years since primary diagnosis | Yuan et al, 201717 |
43/F | Heart failure symptoms | Small intestinal | ALK neg | NA | 1 year | Left ventricle, stomach, liver, vertebra, and pelvic bones | Surgery and chemotherapy | Dead 9 months after surgery | Zorinas et al, 201718 |
16/F | A localized left shoulder mass around the subacromial region | Left shoulder | ALK pos | EML4-ALK translocation | 45 months | Left clavicle, the arm, and the anterior chest wall soft tissues | Surgery, chemotherapy, radiotherapy and targeted therapy | Remains in complete remission on follow-up 3 years | Gaudichon et al, 201619 |
49/F | Cough | Lower lobe of left lung | ALK pos | ALK-gene rearrangement | 4 months | Right anterior-end of third-rib and right adrenal gland | Surgery and targeted therapy | NR | Sethi et al, 201520 |
28/F | Post-prandial abdominal pain | Abdominal extensive solid masses involving multiple viscera | ALK neg | NA | Continuing progression | Vertebral body, liver and peritoneum | Surgery and chemotherapy | Dead | Kim et al, 201521 |
27/F | A painless palpable mass in the upper outer quadrant of the right breast | Right breast | ALK neg | NA | 2 years | The upper inner quadrant of the right breast and right cervical area | Surgery | NR | Choi et al, 201522 |
36/M | Hematochezia, tenesmus, and constipation | Rectum | ALK pos | NA | 18 months | The pelvic floor muscles, sacrococcyx, pre-sacral fascia | Surgery and chemotherapy | Follow-up every 6 months and disease-free | Sun et al, 201423 |
26/M | Chronic nonproductive cough | Mediastinum | ALK neg | NA | Continuing progression | Lymph nodes and the thoracic vertebra | Hormonotherapy and chemotherapy | No radiological evidence of tumor progression or recurrence for 7 months | Kubo et al, 201224 |
52/M | Dyspnea and cough | Upper lobes of bilateral lung | NA | NA | No | Left adrenal gland | Surgery | Alive and well, without recurrence on follow-up 1 year | Carillo et al, 201125 |
Abbreviations: ALK, anaplastic lymphoma kinase; F, female; M, male; NA, not available; neg, negative; NR, not reported; pos, positive.